Takahashi, Yoshiko
Narita, Shintaro
Shiota, Masaki
Miura, Masatomo
Kagaya, Hideaki
Kashima, Soki
Yamamoto, Ryohei
Nara, Taketoshi
Huang, Mingguo
Numakura, Kazuyuki
Saito, Mitsuru
Eto, Masatoshi
Habuchi, Tomonori
Funding for this research was provided by:
Janssen Pharmaceutical K.K.
AstraZeneca K.K.
Astellas Pharma Inc.
Daiichi Sankyo Company
Takeda Pharmaceutical Company Ltd
Sanofi S.A.
Bayer AG.
Mochida Pharmaceutical Co.
Article History
Received: 24 September 2022
Accepted: 5 November 2022
First Online: 15 November 2022
Declarations
:
: This study was supported in part by the research grant from the Nakatomi Foundation and the MEXT/JSPS (Kakenhi, No. 19K09663, 21K06592, 19K18551, 19K16706, 21H03064).
: The study protocol was conducted in accordance with the Declaration of Helsinki. The protocol was approved by the Independent Ethics Committee.
: All patients provided written informed consent prior to undergoing any study-specific procedure.
: Not applicable.
: Shintaro Narita received honoraria from Janssen Pharmaceutical K.K. Masaaki Shiota received honoraria from Janssen Pharmaceutical K.K., AstraZeneca K.K., and Astellas Pharma Inc.; and research funding support from Daiichi Sankyo Company. Tomonori Habuchi also received honoraria from Janssen Pharmaceutical K.K.; Takeda Pharmaceutical Company Ltd.; Astellas Pharma Inc.; Daiichi Sankyo Company, Ltd.; AstraZeneca K.K.; Sanofi S.A.; and Bayer AG. Tomonori Habuchi also received research funding support from Mochida Pharmaceutical Co. The other authors have no disclosures.